Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma-Reference-Cited by-同舟云学术

Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma

Published:2023-07 Issue: Volume:565 Page:216218
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Luo Hongmei,Feng Yu,Wang Fangfang,Lin Zhimei,Huang Jingcao,Li Qian,Wang Xin,Liu Xiang,Zhai Xinyu,Gao Qianwen,Li Lingfeng,Zhang Yue,Wen Jingjing,Zhang Li,Niu Ting,Zheng Yuhuan^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Multiple myeloma: every year a new standard?;Rajkumar;Hematol. Oncol.,2019

2. Diagnosis and management of multiple myeloma: a review;Cowan;JAMA,2022

3. What is multiple myeloma?;Silberstein;JAMA,2022

4. Genome instability in multiple myeloma;Neuse;Leukemia,2020

5. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma;Vdovin;Nat. Commun.,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib;Cell Death & Disease;2024-08-13

2. Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation;Molecular Oncology;2024-07-04

3. Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential;Journal of Cellular and Molecular Medicine;2024-07

4. Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma;World Journal of Clinical Oncology;2024-01-24

5. Cx43 can form functional channels at the nuclear envelope and modulate gene expression in cardiac cells;Open Biology;2023-11